Authors: | Greenberg, P. L.; Stone, R. M.; Abaza, Y.; Al-Kali, A.; Anand, S.; Ball, B.; Bennett, J. M.; Borate, U.; Brunner, A. M.; Chai-Ho, W.; Curtin, P.; DeZern, A. E.; Gaensler, K.; Gahvari, Z.; Garcia-Manero, G.; Griffiths, E. A.; Haque, T.; Jacoby, M.; Jonas, B. A.; Keel, S.; Khanal, R.; Kishtagari, A.; Madanat, Y.; Maness, L. J.; McCurdy, S. R.; McMahon, C.; Odenike, O.; Osman, A.; Reddy, V. V.; Sallman, D. A.; Sayar, H.; Shallis, R.; Singh, A.; Tanaka, T.; Thota, S.; Kovach, E.; Nguyen, J.; Hochstetler, C. |
Title: | Myelodysplastic syndromes, version 2.2025: Featured updates to the NCCN guidelines |
Abstract: | The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics. © 2025 National Comprehensive Cancer Network® (NCCN®). All rights reserved. |
Keywords: | practice guideline; myelodysplastic syndrome; diagnosis; disease management; therapy; myelodysplastic syndromes; humans; prognosis; human |
Journal Title: | Journal of the National Comprehensive Cancer Network |
Volume: | 23 |
Issue: | 3 |
ISSN: | 1540-1405 |
Publisher: | Harborside Press |
Date Published: | 2025-03-01 |
Start Page: | 66 |
End Page: | 75 |
Language: | English |
DOI: | 10.6004/jnccn.2025.0013 |
PUBMED: | 40073835 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | Source: Scopus |